Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03783897 · ClinicalTrials.gov registry record · Phase 1
A Drug-drug Interaction Study to Investigate the Effect of Coadministration of EDP-305 on the PK of a Combined Oral Contraceptive in Healthy Female Subjects
A Phase 1 study of NASH - Nonalcoholic Steatohepatitis, sponsored by Enanta Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 43
- Enrollment target
- 1
- Study location
NCT03783897 is a Phase 1 study of NASH - Nonalcoholic Steatohepatitis that has completed, run by Enanta Pharmaceuticals. The registered enrollment target is 43 participants, below the 267-participant average among 27 other NASH - Nonalcoholic Steatohepatitis trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03783897, a Phase 1 study of NASH - Nonalcoholic Steatohepatitis, has completed, sponsored by Enanta Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 43 participants
- Enrollment target
- 1
- Study location
Study Summary
A Phase 1, Open-label, Fixed-sequence Study to Investigate the Effects of EDP 305 on the Pharmacokinetics of a Combined Oral Contraceptive in Healthy Adult Female Subjects
Conditions Studied
Interventions
- DRUG EDP-305
- DRUG Oral Contraceptive
Study Locations (1)
Wisconsin
- Covance Clinical Research Unit - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2018-11-27 |
| Est. Completion | 2019-06-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03783897
The ClinicalTrials.gov registry entry for NCT03783897 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 267-participant average among 27 other NASH - Nonalcoholic Steatohepatitis trials with a reported enrollment target (84% lower). The listed sponsor is Enanta Pharmaceuticals, which has 36 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with NASH - Nonalcoholic Steatohepatitis appearing as the primary indexed condition, and to 2 interventions - of which EDP-305 is the first listed.
NCT03783897 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.
Frequently Asked Questions
What is clinical trial NCT03783897 about?
NCT03783897 is a clinical study titled "A Drug-drug Interaction Study to Investigate the Effect of Coadministration of EDP-305 on the PK of a Combined Oral Contraceptive in Healthy Female Subjects". A Phase 1, Open-label, Fixed-sequence Study to Investigate the Effects of EDP 305 on the Pharmacokinetics of a Combined Oral Contraceptive in Healthy Adult Female Subjects
What is the current status of trial NCT03783897?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 43 participants. The study started on 2018-11-27. Estimated completion is 2019-06-18.
What conditions does trial NCT03783897 study?
This clinical trial studies the following conditions: NASH - Nonalcoholic Steatohepatitis.
What interventions are being tested in trial NCT03783897?
The interventions under investigation include: EDP-305 (DRUG), Oral Contraceptive (DRUG).
Who is sponsoring clinical trial NCT03783897?
This trial is sponsored by Enanta Pharmaceuticals, which has 36 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03783897 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for NASH - Nonalcoholic Steatohepatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PK Study of Liquid Formulation of BIO89-100 in Subjects With NASH With Compensation Cirrhosis
COMPLETED · Phase 1
-
Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects
COMPLETED · Phase 1
-
Study of Gemcabene in Adults With FPLD
COMPLETED · Phase 1
-
Investigating the Link Between Type 2 Immunity and NAFLD in Human Obesity
RECRUITING
-
Non-Invasive Quantification of Liver Health in NASH (N-QUAN)
RECRUITING · NA
-
Feasibility, Safety and Acceptability of a Mobile Health Delivered Exercise Training Program in Patients With Nonalcoholic Steatohepatitis
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.